Physician profile
Daniel J Lama
NPI 1972517928
$9,732.60
in general payments reported to CMS, 2019-2025
39 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,513 · 2020: $1,608 · 2021: $1,218 · 2022: $1,231 · 2023: $2,159 · 2024: $961 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,096 · Consulting Fee: $958 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,096.28 |
| Consulting Fee | $958.00 |
| Education | $108.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,306.48 | 2019-2025 | |
| Boston Scientific Corporation | $1,230.98 | 2019-2021 | |
| Astellas Pharma US INC | $923.05 | 2019-2024 | Xtandi, Myrbetriq |
| Dendreon Pharmaceuticals LLC | $890.45 | 2019-2025 | Provenge |
| Abbvie INC. | $815.89 | 2020-2025 | |
| Janssen Biotech, INC. | $805.32 | 2019-2025 | Erleada, Akeega, Balversa |
| Astrazeneca Pharmaceuticals LP | $396.42 | 2020-2024 | Lynparza |
| Biotissue Holdings INC. | $337.37 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $316.39 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $311.40 | 2019-2025 | |
| Procept Biorobotics Corporation | $309.94 | 2023 | Aquabeam Robotic System |
| Ferring Pharmaceuticals INC. | $280.66 | 2019-2025 | Adstiladrin |
| Coloplast Corp | $196.81 | 2019-2023 | Speedicath |
| Tolmar Pharmaceuticals, INC. | $172.89 | 2019-2021 | |
| Tolmar, INC. | $165.82 | 2023-2025 | Eligard |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $138.61 | 2022-2025 | Prolaris |
| Teleflex LLC | $118.76 | 2021-2024 | Urolift |
| Comsort, INC | $100.00 | 2019 | |
| Intuitive Surgical, INC. | $100.00 | 2024 | |
| Myovant Sciences INC. | $98.53 | 2021-2022 | |
| Agiliti Health, INC. | $84.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $74.48 | 2024-2025 | |
| Urogen Pharma, INC. | $72.43 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $64.04 | 2019-2021 | |
| Convatec INC. | $55.02 | 2023-2025 | |
| Neotract INC. | $50.58 | 2019-2020 | |
| Urovant Sciences INC | $42.74 | 2022 | |
| Medtronic, INC. | $40.00 | 2022 | |
| Immunitybio, INC. | $33.34 | 2025 | |
| Hollister Incorporated | $31.19 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $28.15 | 2022 | |
| Foundation Medicine, INC. | $27.50 | 2021-2022 | |
| Amgen INC. | $25.41 | 2022 | |
| Accord Healthcare, INC. | $24.30 | 2024 | |
| Cardinal Health 414 LLC | $21.55 | 2025 | |
| Blue Earth Diagnostics | $20.88 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $12.06 | 2021 | |
| Janssen Scientific Affairs, LLC | $7.17 | 2025 | Erleada |
| Travere Therapeutics, INC. | $1.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.